Literature DB >> 22942885

Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Marina B Klein1, Jean-Guy Baril, Marc-André Charron, Claude Fortin, Richard Lalonde, Marie-France Matte, Marc Poliquin, Annie Talbot, Rachel Therrien, Cécile Tremblay, Benoît Trottier, Irina Tsarevsky, Jean-Pierre Villeneuve.   

Abstract

The management and treatment of HIV and hepatitis B virus (HBV)-coinfected patients present specific challenges for clinicians. The morbidity and mortality related to these concomitant infections are growing concerns, while the use of antiviral drugs effective against both viruses complicates therapeutic decision making. The present document provides guidelines for physicians regarding care and treatment of patients coinfected with HIV and HBV. Primary prevention of HBV in HIV-positive patients is achieved through appropriate vaccination schedules. Follow-up before treatment of HBV may include liver biopsy, screening for hepatocellular carcinoma and testing for esophageal varicies in cases of cirrhosis. In HBV-infected patients requiring treatment, recommendations regarding initiation, duration and choice of first-line drugs are made. Finally, in the case of resistance, appropriate alternative therapies are necessary.

Entities:  

Keywords:  Antiretroviral therapy; HIV; HIV coinfection; Hepatitis B; Resistance; Vaccination

Year:  2011        PMID: 22942885      PMCID: PMC3200371          DOI: 10.1155/2011/686918

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  84 in total

1.  Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.

Authors:  Florian van Bömmel; Bernhard Zöllner; Christoph Sarrazin; Ulrich Spengler; Dietrich Hüppe; Bernd Möller; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

2.  An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

Authors:  M Nelson; S Portsmouth; J Stebbing; M Atkins; A Barr; G Matthews; D Pillay; M Fisher; M Bower; B Gazzard
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

3.  Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection.

Authors:  R J Gilson; A E Hawkins; M R Beecham; E Ross; J Waite; M Briggs; T McNally; G E Kelly; R S Tedder; I V Weller
Journal:  AIDS       Date:  1997-04       Impact factor: 4.177

4.  Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects.

Authors:  Ana Paula Rocha Veiga; Jorge Casseb; Alberto J S Duarte
Journal:  Vaccine       Date:  2006-07-18       Impact factor: 3.641

5.  Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.

Authors:  A Erhardt; D Blondin; K Hauck; A Sagir; T Kohnle; T Heintges; D Häussinger
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 6.  Assessment of liver fibrosis in co-infected patients.

Authors:  T Barry Kelleher; Nezam Afdhal
Journal:  J Hepatol       Date:  2005-11-28       Impact factor: 25.083

7.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

8.  Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers.

Authors:  D D Douglas; H F Taswell; J Rakela; D Rabe
Journal:  Transfusion       Date:  1993-03       Impact factor: 3.157

9.  Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe.

Authors:  F Bonino; F Rosina; M Rizzetto; R Rizzi; E Chiaberge; R Tardanico; F Callea; G Verme
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

10.  Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B.

Authors:  G Fattovich; M Rugge; L Brollo; P Pontisso; F Noventa; M Guido; A Alberti; G Realdi
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.